Robert Weisskoff, a Senior Partner at F-Prime Capital, invests in Seed through Series B stages across Medical Devices. See sector focus and contact routes.
Robert Weisskoff, a Senior Partner at F-Prime Capital, invests in Seed through Series B stages across Medical Devices, Pharmaceuticals, BioTech, Health IT, and Health & Hospital Services, with typical check sizes ranging from $100K to $10.0M and a sweet spot of $5.0M[1][2]. His notable portfolio includes Shinobi Therapeutics ($51M Series A), Adela ($60M Series A for cancer detection via genome-wide methylation), and Affinia Therapeutics ($110M Series B for gene therapy), for which he serves on the board[1][2][5][8]. While his specific personal thesis is not explicitly detailed, his investments align with F-Prime Capital’s broader strategy of pursuing “technical-risk-yes, regulatory-risk-no” opportunities in rare diseases and gene therapy with clear FDA pathways[10].
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Boston.
Investors like Robert Weisskoff · Full investor directory · Investor access · Company funding database